Onxeo Plans Clinical Trials For Three Phase III Orphan Oncologics
This article was originally published in The Pink Sheet Daily
Executive Summary
The year-old pan-European biotech is targeting advanced liver cancer, severe mucositis and the rare cancer, peripheral T-cell lymphoma, for its first products in the orphan oncology niche.